BioTuesdays

Tag - Stifel

Markets

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

November 25, 2019
Genocea Biosciences
Markets

Stifel ups Genocea Biosciences PT to $18 from $5

Stifel hiked its price target for Genocea Biosciences (NASDAQ:GNCA) to $18 from $5 after raising the probability of success to 20% from 15% for Phase 1 efficacy data of the company’s cancer vaccine, GEN-009. The stock...

November 11, 2019
Senseonics
Markets

Stifel starts Senseonics at buy; PT $2

Stifel initiated coverage of Senseonics Holdings (NYSE American:SENS) with a “buy” rating and $2 price target. The stock closed at 95 cents on Oct. 22. Senseonics is an emerging company with a long-duration, implantable...

October 23, 2019
IGM Biosciences
Markets

Stifel starts IGM Biosciences at buy; PT $32

Stifel launched coverage of IGM Biosciences (NASDAQ:IGMS) with a “buy” rating and $32 price target. The stock closed at $17.25 on Oct. 11. “We believe the company’s first/only-in-class, IgM-based antibody platform...

October 14, 2019
Markets

Stifel cuts Inogen to hold; PT to $48 from $85

Stifel downgraded Inogen (NASDAQ:INGN) to “hold” from “buy” and lowered its price target to $48 from $85 after the company’s second quarter sales missed consensus estimates and it reduced 2019 guidance. The stock closed...

August 8, 2019
Markets

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Stifel downgraded Vanda Pharmaceuticals (NASDAQ:VNDA) to “hold” from “buy” and cut its price target to $17 from $26 after a deeper look into a FDA lawsuit against the company, its pipeline and execution risk. The stock...

July 25, 2019
Markets

Stifel cuts Viveve Medical to hold; PT to $1 from $3

Stifel downgraded Viveve Medical (NASDAQ:VIVE) to “hold” from “buy” and lowered its price target to $1 from $3 after the company’s LIBERATE-International trial for stress urinary incontinence (SUI) missed its primary...

July 23, 2019

Subscribe

Sign up to our weekly BioTuesdays newsletter.